New mRNA expression platform and its applications
By using a novel mRNA expression platform constructed from virus-derived IRES and UTR, the problems of stability and short expression duration of existing mRNA vaccines have been solved, achieving efficient and safe induction of immune responses and simplifying production while reducing costs.
Patent Information
- Application Number
- CN202580028973.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-18
- Filing Date
- 2025-03-24
- Publication Date
- 2026-11-17
AI Technical Summary
Existing mRNA vaccines have low stability, short expression duration, require multiple injections, and may lead to excessive immune response and side effects. They are also complex and costly to manufacture.
A novel mRNA expression platform based on viral-derived internal ribosome entry sites (IRES), 5'-UTR, and 3'-UTR was developed. The construct contains a 5'-UTR region, an IRES regulatory element, a nucleotide sequence encoding the target peptide, and a 3'-UTR region, avoiding 5' caps and nucleic acid modifications. mRNA was produced using IVT technology.
It achieves high stability and long-term expression of mRNA, reduces the number of injections, lowers the risk of excessive immune response, simplifies the manufacturing process and reduces costs, while inducing a strong immune response.
Smart Images

Figure CN123124991A_ABST
Abstract
Description
Technical Field
[0001] This disclosure relates to novel mRNA expression platforms based on viral-derived internal ribosome entry sites (IRES), 5'-UTR, and 3'-UTR, and their uses. Background Technology
[0002] mRNA is an intermediary that connects the translation of DNA, which encodes protein information, with the production of proteins by ribosomes in the cytoplasm. The optimal in vitro transcribed mRNA for therapeutic purposes is produced using T7, T3, or Sp6 phage RNA polymerases from a linear DNA template. The resulting RNA should typically have an open reading frame (ORF) encoding the target protein, an untranslated region, a 5'-cap, and a poly(A) tail.
[0003] Based on such mRNAs, mRNA vaccines have been extensively researched and developed during the global pandemic caused by Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). In the case of existing commercially available mRNAs, additional modifications (such as 5' capping, 3' poly-A tailing, and replacement of uridine with 1-methyl-pseudouridine) are essentially necessary to enhance stability and expression efficiency. However, due to the relatively low stability and short duration of expression of mRNAs themselves, such mRNA vaccines require two or more doses, and problems of severe over-immune responses and side effects due to over-injection of lipid-containing mRNA vaccines have been consistently observed. For example, the COVID-19 mRNA vaccines from Pfizer Inc. and Moderna Inc. use modified nucleic acids linked to a 5' cap and containing m1Ψ (pseudouridine); although this process can induce a high immune response, it complicates the manufacturing process and increases production costs, and frameshifts are known to occur during ribosomal translation, leading to known problems such as the emergence of mutant antigens. Therefore, various attempts have been made to address these known problems of existing mRNA vaccines.
[0004] Therefore, after unremitting efforts, the inventors completed this invention by developing a new mRNA expression platform based on novel viral internal ribosome entry sites (IRES), 5'-UTR, and 3'-UTR. Summary of the Invention
[0005] [Technical Issues]
[0006] One object of this disclosure is to provide an mRNA construct comprising, from 5' to 3', the following: a 5'-UTR region; an internal ribosome entry site (IRES) regulatory element; a nucleotide sequence encoding a target peptide; a 3'-UTR region; and a poly(A) nucleotide sequence.
[0007] Another object of this disclosure is to provide a gene construct and a vector containing the gene construct, said gene construct comprising a DNA nucleotide sequence corresponding to or complementary to the nucleotide sequence of said mRNA construct.
[0008] Another object of this disclosure is to provide a pharmaceutical composition comprising the mRNA construct, the gene construct, and / or the vector.
[0009] Another object of this disclosure is to provide a vaccine composition comprising the mRNA construct, the gene construct, and / or the vector.
[0010] The technical problems to be solved by this disclosure are not limited to those described above, and other problems not mentioned herein will be clearly understood by those skilled in the art from the following description.
[0011] [Technical Solution]
[0012] This will be described in detail below. Furthermore, each description and embodiment disclosed in this disclosure can also be applied to every other description and embodiment. That is, all combinations of the multiple elements disclosed in this disclosure fall within the scope of this disclosure. Additionally, the scope of this disclosure should not be construed as being limited by the specific description described below.
[0013] Furthermore, the terminology used in this disclosure is for illustrative purposes only and should not be construed as restrictive. Unless the context clearly indicates otherwise, singular expressions include plural expressions. In this disclosure, terms such as “comprising / including” or “having” are intended to indicate the presence of the features, figures, steps, operations, components, parts, or combinations thereof described in the specification, and should be understood not to preclude the possibility of the presence or addition of one or more other features, figures, steps, operations, components, parts, or combinations thereof.
[0014] Furthermore, unless otherwise defined, all terms used herein (including technical and scientific terms) shall have the same meaning as commonly understood by one of ordinary skill in the art to which the embodiments pertain. Terms as defined in common dictionaries shall be interpreted as having meaning consistent with their meaning in the context of the relevant field, and shall not be interpreted in an idealized or overly formal sense unless expressly defined in this application.
[0015] Furthermore, to avoid redundancy, descriptions of repeated content will be omitted below. That is, the content of this disclosure is not limited to the following, and the content of this disclosure should be interpreted in its entirety.
[0016] In this disclosure, the term "homology" refers to a sequence that, when aligned with any other sequence to maximize its correspondence with the sequence of this disclosure and analyzed using algorithms commonly used in the art, has at least 80% homology (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%), more preferably 90% homology (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%). Regarding percentage homology, all integers of 80% or greater and 100% or less, as well as decimals in between, are included within the scope of this disclosure.
[0017] The term "fragment" as used in this disclosure can generally refer to a shorter portion of a full-length sequence, such as a nucleic acid sequence or an amino acid sequence, while retaining its intended function. Therefore, a fragment typically consists of a sequence identical to the corresponding segment within the full-length sequence. In the context of this disclosure, a preferred fragment of the sequence consists of nucleotides or amino acids corresponding to a continuous segment of an entity (e.g., a continuous segment of the intramolecular entity from which the fragment originates), comprising at least 40%, 50%, 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% of the total (i.e., full-length) molecule from which the fragment originates.
[0018] The term "variant" used in this specification for nucleic acid sequences will be recognized and understood by those skilled in the art, and is intended to refer to, for example, a variant of a nucleic acid sequence derived from another nucleic acid sequence. For example, a variant of a nucleic acid sequence may exhibit one or more nucleotide deletions, insertions, additions, and / or substitutions compared to the nucleic acid sequence from which the variant originates. A variant of a nucleic acid sequence may have at least 40%, 50%, 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with the nucleic acid sequence from which the variant originates. A variant is a functional variant because it retains at least 40%, 50%, 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more of the function of its source sequence. In one embodiment, a “variant” of a nucleic acid sequence may have at least 40%, 50%, 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% nucleotide identity over a segment of at least 10, 20, 30, 50, 75, or 100 nucleotides of such a nucleic acid sequence.
[0019] The term "functional variant" in this disclosure refers to at least one active peptide variant or polynucleotide variant having a sequence.
[0020] The novel mRNA expression platform disclosed herein utilizes internal ribosome entry sites (IRES) derived from viruses, particularly encephalomyocarditis virus (EMCV), to provide a novel uncapped / unmodified mRNA expression system that does not use 5'-caps and modified nucleic acids, thereby effectively inducing immune responses while exhibiting excellent antigen expression performance.
[0021] Therefore, this disclosure provides an mRNA construct comprising, from 5' to 3', the following components in sequence: a 5'-UTR region; an internal ribosome entry site (IRES) regulatory element; an RNA sequence encoding a target peptide; a 3'-UTR region; and a poly(A) nucleotide sequence. In this disclosure, since the IRES regulatory element is not a translated coding region, it belongs to the 5'-UTR region; however, in this patent, only the RNA sequence preceding the IRES (excluding the IRES itself) is designated as the 5'-UTR region, and the IRES portion is designated separately as IRES.
[0022] An untranslated region (UTR) is a region that is transcribed but not translated into an amino acid sequence, or a corresponding region within an RNA molecule (such as mRNA). UTRs can be located upstream of an open reading frame and are called the 5'-UTR. UTRs can also be located downstream of an open reading frame encoding a chimeric protein and are called the 3'-UTR.
[0023] The 5'-untranslated region (5'-UTR) is the non-coding region of mRNA located at the 5' end of the translation initiation sequence (AUG) and plays a role in assisting or regulating ribosomal translation. Exemplary 5'-UTR regions according to this disclosure can be cloverleaf structures of poliovirus, rhinovirus, or Coxsackievirus. Specifically, cloverleaf structures of poliovirus (SEQ ID NO: 2), rhinovirus (SEQ ID NO: 8), and Coxsackievirus (SEQ ID NO: 9) are considered. Specifically, the 5'-UTR region can contain any nucleic acid sequence selected from SEQ ID NO: 2, 8, and 9, a nucleic acid sequence having at least 80% homology therewith, a fragment thereof, or a functional variant thereof, and more preferably, it can contain the cloverleaf structure of poliovirus of SEQ ID NO: 2, a nucleic acid sequence having at least 80% homology therewith, a fragment thereof, or a functional variant thereof. In one embodiment, the 5'-UTR according to this disclosure is SEQ ID NO: 2, 8, or 9. Preferably, it may be SEQ ID NO: 2.
[0024] It is known that the 5'-UTR of poliovirus enhances the stability of poliovirus mRNA.
[0025] The 3'-UTR region is the mRNA region located at the 3' end of the translation stop codon (i.e., the stop codon), and is essential for targeting transcripts to specific cellular compartments, and is particularly necessary for mRNA localization and protein synthesis in highly polarized or differentiated cells.
[0026] In this disclosure, the 3'-UTR region can be the 3'-UTR of poliovirus, the 3'-UTR of rhinovirus, or the 3'-UTR of Coxsackievirus. Exemplary 3'-UTRs can include the 3'-UTR of poliovirus 1 (SEQ ID NO: 3), the 3'-UTR of Coxsackievirus (SEQ ID NO: 10), and the 3'-UTR of rhinovirus (SEQ ID NO: 11). Specifically, the 3'-UTR region can contain any nucleic acid sequence selected from SEQ ID NO: 3, 10, and 11, a sequence having at least 80% homology therewith, a fragment thereof, or a functional variant thereof. More preferably, it can contain the 3'-UTR of poliovirus SEQ ID NO: 3, a nucleic acid sequence having at least 80% homology therewith, a fragment thereof, or a functional variant thereof. In one embodiment, the 3'-UTR is SEQ ID NO: 3, 10, or 11. Preferably, it can be SEQ ID NO: 3. Such a 3'-UTR has the advantage of improving mRNA stability or enhancing translation efficiency in specific environments.
[0027] Here, the 3'-UTR may originate from the same virus as the 5'-UTR, or it may originate from a different virus.
[0028] Internal ribosome entry site (IRES) regulatory elements are a portion of mRNA that forms a three-dimensional structure containing a stem-loop structure, serving as an internal ribosome entry site or ribosome binding site to induce translation initiation of the mRNA. It is linked to a coding region (CR) composed of an open reading frame (ORF) encoding the target peptide to aid in the expression of the target peptide. For example, the coding region (CR) is located, for example, on the 3' side of an IRES sequence or a 5'-UTR containing an IRES sequence, and forms a target sequence (TS) encoding the target peptide. The target nucleic acid molecule is RNA, and the coding region (CR) can consist of a transcript sequence of an open reading frame encoding the target peptide. In particular, the system according to this disclosure is optimized for protein expression and is characterized by good translation even in the absence of a cap structure at the 5' end.
[0029] That is, according to this disclosure, the internal ribosome entry site (IRES) regulatory element refers to the IRES nucleotide sequence that is effectively linked to a coding region (CR) inserted in the form of an open reading frame.
[0030] In the mRNA construct according to this disclosure, IRES is the region to which the translation initiation complex binds during the translation of a peptide and / or protein expressed by a coding region (CR), and IRES is a cis-acting nucleotide sequence that forms complex secondary and tertiary structures to induce translation of the coding region (CR).
[0031] The IRES regulatory element is derived from, but is not limited to, encephalomyocarditis virus (EMCV). For example, the IRES can be a wild-type IRES from EMCV or an IRES with a slight mutation added. Such a sequence can be represented by, for example, SEQ ID NO: 1. Alternatively, the IRES regulatory element is derived from, but is not limited to, coxsackievirus (CV) or coxsackievirus B3 (CVB3). For example, the IRES can be a wild-type IRES from CV or CVB3 or an IRES with a slight mutation added. Such a sequence can be represented by, for example, SEQ ID NO: 7. That is, the IRES regulatory element according to this disclosure can be an IRES derived from encephalomyocarditis virus (EMCV), or an IRES derived from coxsackievirus or coxsackievirus B3 (CVB3). In addition, the IRES regulatory element can comprise any nucleic acid sequence selected from SEQ ID NO: 1 or 7, a sequence having at least 80% homology with it, a fragment thereof, or a functional variant thereof, and is preferably SEQ ID NO: 1 or SEQ ID NO: 7, and more preferably SEQ ID NO: 1.
[0032] According to this disclosure, IRES promote protein translation initiation. Specifically, when using IRES derived from encephalomyocarditis virus (EMCV) or from Coxsackievirus (CV) or Coxsackievirus B3 (CVB3), the target gene can be expressed efficiently, and if the target gene is an immune-enhancing gene, immune enhancement in the target tissue can be effectively induced. In particular, the viral-derived IRES described above in this disclosure have the advantage of inducing strong protein expression even in various cell types and environments.
[0033] Optionally, nucleic acid sequences that can improve the expression efficiency of coding regions (CRs) linked in the form of open reading frames (ORFs) can also be inserted. That is, multiple adenosines or nucleotides that can be transcribed into multiple adenosines (multiple adenosines; MA) can be inserted adjacent to the IRES component. For example, multiple adenosines (MA) can be inserted to the 5' side of the expression control sequence (ECS) for the target peptide in the RNA transcript, but the location where multiple adenosines (MA) can be inserted is not limited to this. In this case, other bases besides adenosines can be added or omitted.
[0034] Multiple adenosines (MAs) that may be inserted adjacent to the IRES regulatory element are shown in the form of transcripts. In one exemplary embodiment, 20 to 400, preferably 30 to 300, more preferably 30 to 200, and most preferably 30 to 100 consecutive adenosines or nucleotides that can be transcribed into adenosines may be inserted adjacent to an expression control sequence (ECS) having an IRES nucleotide sequence.
[0035] The target peptide is the peptide to be produced and refers to any peptide that can be expressed using a transcription or translation system. For example, the target peptide can be a hormone, hormone analogue, enzyme, enzyme inhibitor, receptor and receptor fragment, antigen and antigen fragment or analog, antibody and antibody fragment, single-chain antibody, structural protein, toxin protein, etc., or any combination thereof. Preferably, the target peptide can be an antigen or a fragment thereof. An "antigen" refers to a molecule or structure containing one or more epitopes that induce, trigger, enhance, or support cellular and / or humoral immune responses. Antigens can include proteins and peptides, for example, derived from pathogens (e.g., viruses, bacteria, fungi, protozoa, plants) or from tumors.
[0036] The RNA sequence encoding the target peptide according to this disclosure is in RNA form, thus providing superior performance compared to nucleic acid molecules using DNA. In particular, mRNA synthesis can be performed using in vitro transcription (IVT), and it should be considered different from gene expression systems using DNA because it enables faster and higher protein expression compared to gene expression systems using conventional DNA.
[0037] First, due to its nature, unlike DNA-based nucleic acid molecules, RNA-based nucleic acid molecules do not need to enter the host cell nucleus to be transcribed into mRNA. Since RNA-based nucleic acid molecules can synthesize desired peptides or proteins in the cytoplasm, they are superior to DNA-based nucleic acid molecules in terms of expression within the human body. That is, RNA-based nucleic acid molecules have no possibility of integrating into the host chromosome within the nucleus; antibiotic resistance genes (which are selective markers used for selective production in host cells) are unnecessary for producing RNA-based nucleic acid molecules; and because RNA has a shorter half-life than DNA, it does not induce durable genetic transformation. In other words, while conventional nucleic acid molecules are delivered to cells and activated only for a short time to express target peptides / proteins, and are destroyed by enzymatic reactions within days, the specific immune response to the initially expressed target peptide / protein remains.
[0038] Second, compared to DNA-based nucleic acid molecules, RNA-based nucleic acid molecules can induce the desired in vivo immune response even when used in relatively small amounts. As mentioned above, unlike DNA-based nucleic acid molecules, RNA-based nucleic acid molecules do not need to enter the nucleus and only need to pass through the cell membrane. Therefore, when using RNA-based nucleic acid molecules, target peptides / proteins can be expressed to the same extent, even in smaller quantities than DNA-based nucleic acid molecules.
[0039] Third, because all manufacturing processes can be controlled manually, vaccines can be safely produced in small-scale Good Manufacturing Practice (GMP) facilities without the risk of biological contamination. That is, since RNA-form nucleic acid molecules only require small-scale GMP laboratory-level facilities and do not require direct handling of infectious agents (viruses or pathogenic microorganisms), multiple vaccines can be rapidly manufactured and produced.
[0040] Fourth, compared to naked DNA nucleic acid molecules, RNA-based nucleic acid molecules can induce a stronger immune response. This is thought to be due to a synergistic interaction between innate and adaptive immune responses, the innate immune response being induced by the stem-loop structure of RNA nucleic acid molecules and the intrinsic properties of RNA itself, and the adaptive immune response being induced by target peptides / proteins expressed in immunized host cells.
[0041] Fifth, RNA nucleic acid molecules are readily produced. As mentioned above, when producing RNA nucleic acid molecules, large quantities can be generated solely through in vitro transcription (IVT). Recently, reagents associated with IVT reactions, particularly DNA-dependent RNA polymerases, have been improved, enabling the rapid production of large amounts of RNA within 1 to 2 weeks using small amounts of DNA template. Furthermore, multiple antigens designed to induce an immune response can be prepared simultaneously and mixed before immunization.
[0042] In light of this background, the mRNA construct according to this disclosure, by including the aforementioned components, also has high applicability in IVT mRNA expression systems.
[0043] Specifically, the mRNA construct according to this disclosure may not contain a 5' cap structure. Furthermore, it may not contain any modified nucleic acids. Such modified nucleic acids include, for example, N1-methylpseuuridine, 5-methylcytosine, etc., and refer to any and all forms of nucleic acid modification, but are not limited thereto. Preferably, the mRNA construct does not contain N1-methylpseuuridine.
[0044] A poly(A) nucleotide sequence is a nucleotide sequence in which multiple adenosine monophosphates are linked by phosphodiester bonds. The length of a poly(A) nucleotide sequence can be from 20 nt to 500 nt, for example, 30 nt to 450 nt, 50 nt to 400 nt, or 100 nt to 350 nt.
[0045] The poly(A) nucleotide sequence can be placed downstream of the nucleotide sequence encoding the target peptide. Downstream refers to the portion after the 3' end of the nucleotide sequence encoding the target peptide. Therefore, the poly(A) nucleotide sequence can be placed after the 3' end of the nucleotide sequence encoding the target peptide. In this case, the poly(A) nucleotide sequence can be directly attached to the 3' end of the nucleotide sequence encoding the target peptide, or any nucleotide sequence can be inserted between the 3' end of the nucleotide sequence encoding the target peptide and the poly(A) nucleotide sequence.
[0046] As described above, when the mRNA construct is configured such that the poly(A) nucleotide sequence is positioned downstream of the nucleotide sequence encoding the target peptide, the mRNA construct not only exhibits high structural stability in the cytoplasm of the cell after introduction, but also actively induces the expression of the target peptide with full function over an extended period of time.
[0047] In addition, this disclosure provides gene constructs and vectors containing gene constructs, the gene constructs comprising DNA nucleotide sequences corresponding to or complementary to the nucleotide sequences of the mRNA constructs.
[0048] The DNA nucleotide sequence corresponding to the nucleotide sequence of the mRNA construct refers to a DNA nucleotide sequence in which uracil (U) in the mRNA construct's nucleotide sequence is replaced only by thymine (T), while the remaining nucleotide sequences are identical. Additionally, the DNA nucleotide sequence complementary to the mRNA construct refers to a DNA sequence that has an antisense nucleotide sequence relative to the DNA nucleotide sequence corresponding to the mRNA construct's nucleotide sequence.
[0049] Gene constructs containing DNA nucleotide sequences that correspond to or are complementary to the nucleotide sequences of the mRNA constructs disclosed herein can be stored or used in a form contained in a vector.
[0050] For example, in one implementation, cells can be transformed using the vector itself. In this case, cells can be stably or permanently transformed using the gene construct, and the transcription and translation mechanisms of the transformant can be used to transcribe and translate the nucleotide sequence encoding the target peptide from the vector to express the target protein or polypeptide.
[0051] In another embodiment, mRNA can be prepared via in vitro transcription using a vector as a template and subsequently transfected into cells. In this case, cells are transiently transfected with the mRNA, and the target protein or peptide can be translated using the translation mechanisms of the transfected cells to express the target protein or peptide. When using a vector as a template to obtain mRNA via in vitro transcription, the mRNA remains very stable in the cytoplasm of the cell and expresses the target protein or peptide for a long time, even when introduced into the cell, because the poly(A) nucleotide sequence is contained downstream of the nucleotide sequence encoding the target protein or peptide.
[0052] Therefore, another aspect of this disclosure provides a method for generating mRNA with improved stability, which includes in vitro transcription using a vector as a template.
[0053] In vitro transcription refers to the process of synthesizing RNA in vitro using RNA polymerase and its cofactors, substrate NTPs, and template DNA, and is well known to those skilled in the art to which this disclosure pertains. Therefore, those skilled in the art can perform the above process using suitable methods.
[0054] In particular, in the case of the mRNA generation method of this disclosure, since the nucleotide sequence corresponding to or complementary to the poly(A) nucleotide sequence is contained in the gene construct contained in the vector, it is sufficient to perform in vitro transcription as described above, and poly(A) tailing can be performed in vitro without separate or additional addition after in vitro transcription.
[0055] That is, suitable methods of producing gene constructs containing DNA nucleotide sequences that correspond to or are complementary to the nucleotide sequences of mRNA constructs of this disclosure, and vectors containing such gene constructs, will be apparent to those skilled in the art and will be described herein.
[0056] In one instance, the mRNA construct can be generated from plasmid DNA. Those skilled in the art will understand that plasmid DNA is relatively stable. Briefly, competent bacterial cells (e.g., *Escherichia coli*) are transformed with a DNA plasmid encoding the mRNA construct of this disclosure. Individual bacterial colonies are isolated, and the resulting plasmid DNA is amplified in *E. coli* cultures. In one instance, the plasmid DNA is isolated after fermentation. For example, the plasmid DNA is isolated using a commercially available kit (e.g., the Maxiprep DNA kit) or other conventional methods known to those skilled in the art. After isolation, the plasmid DNA is linearized by restriction digestion (i.e., using restriction enzymes). The restriction enzymes are removed using methods known in the art, including, for example, phenol / chloroform extraction and ethanol precipitation.
[0057] In one example, mRNA is produced from a linearized DNA template via in vitro transcription using an RNA polymerase (e.g., T7 RNA polymerase). Following in vitro transcription, the DNA template is removed by DNase digestion or other isolation methods. The mRNA construct according to this disclosure exhibits high stability without a capping process, thus providing the advantages of not requiring additional production processes and being able to be produced without the use of modified nucleic acids. Such mRNA is purified, and various methods for purifying mRNA will be apparent to those skilled in the art. For example, lithium chloride (LiCl) precipitation is used to purify mRNA. In another example, tangential flow filtration (TFF) is used to purify mRNA. After purification, the mRNA is resuspended in, for example, nuclease-free water.
[0058] "Transcriptional control / regulatory sequence" or "transcriptional control / regulatory element" refers to a nucleic acid sequence that regulates nucleic acid transcription. Transcriptional control sequences include promoters (e.g., constitutive or inducible promoters), enhancers, etc. Additionally, the terms "translational control / regulatory sequence" or "translational control / regulatory element" can be used to regulate the translation of nucleic acids from transcripts into proteins or peptides. These expression control sequences / elements, transcriptional control sequences / elements, and / or translational control sequences / elements are effectively linked to the sequence to be expressed, such as the nucleic acid sequence to be transcribed or translated (the target peptide sequence according to this disclosure).
[0059] In this disclosure, the term "effective link" refers to a functional link between a nucleic acid expression regulatory sequence (e.g., a promoter, signal sequence, ribosome binding site, transcription termination sequence, etc.) and another nucleic acid sequence, thereby regulating the transcription and / or translation of the other nucleic acid sequence.
[0060] To insert a coding region (CR) into a nucleic acid molecule, the nucleic acid molecule may contain one or more cloning sites, preferably multiple cloning sites (MCS). These one or more cloning sites may contain one or more restriction endonuclease recognition sites and / or sequences cleaved by restriction enzymes. Restriction enzymes may include naturally occurring restriction enzymes found in bacteria, archaea, etc., as well as artificially prepared restriction enzymes (e.g., restriction enzymes based on the DNA-binding sites of zinc finger nucleases or TAL effectors, or PNA-based PNA enzymes).
[0061] For example, naturally occurring restriction enzymes can be classified into: 1) Type I restriction enzymes (which cleave sites far from the recognition site and require ATP, S-adenosyl-L-methionine, and magnesium ions); 2) Type II restriction enzymes (which cleave specific sites within or slightly away from the recognition site and mostly require magnesium ions); 3) Type III restriction enzymes (which cleave sites slightly away from the recognition site, require ATP, but do not require ATP hydrolysis); 4) Type IV restriction enzymes (which target modified sites, such as methylated, hydroxymethylated, or glucosyl-hydroxymethylated sites); and 5) Type V restriction enzymes (CRISPR cas9-gRNA complex), etc.
[0062] For example, the following restriction enzyme recognition sites and / or restriction enzyme cleavage sites (restriction enzymes) can be used: 5'-ATCGAT-3' (AngI), 5'-AGGCCT-3' (AatI), 5'-TGATCA-3' (AbaI), 5'-GGATCC-3' (BamHI), 5'-GCAGC(N)8-3' (BbvI), 5'-(N)10CGA(N)6TGC(N)12-3' (BcgI), 5'-(N)8GAG(N)5CTC(N)13-3' (BplI), 5'-GTCTC(N)-3' (BsmAI; Alw26I), 5'-ACTGGN-3' (BsrI), 5'-ATCGAT-3' (ClaI), 5'-CTCTTCN-3' (EarI), 5'-CTGAAG(N)16-3' (Eco57I), 5'-GAATTC-3'(EcoRI), 5'-CCWGG-3' (EcoRII; W is A or T), 5'-GATATC-3' (EcoRV), 5'-GGATG(N)9-3'(FokI), 5'-GGCC-3' (HaeIII), 5'-AAGCTT-3' (HindIII), 5'-CCGG-3' (HpaIII), 5'-GGTGA(N)8-3' (HphI), 5'-GGTACC-3' (KpnI), 5'-GATC-3' (MboI), 5'-ACGCGT-3'(MluI), 5'-GCCGGC-3' (NaeI), 5'-GATATG-3' (NdeII), 5'-GCCGGC-3' (NgoMⅣ), 5'-CATG-3' (NlaIII), 5'-GCGGCCGC-3' (NotI), 5'-ATGCAT-3' (NsiI), 5'-TTAATTAA-3' (PacI), 5'-CTGCAG-3' (PstI), 5'-GAGCTC-3' (SacI), 5'-CCGCGG-3' (SacII), 5'-GTCGAC-3' (SalI), 5'-GCATC(N)5-3' (SfaNI), 5'-CCCGGG-3' (SmaI), 5'-TCGA-3' (TaqI), 5'-TCTAGA-3' (XbaI), 5'-CTCGAG-3' (XhoI), and combinations thereof.The coding region (CR), which is the sequence that encodes the target peptide, is located between the 5'-UTR and the 3'-UTR. Together with the 5'-UTR, the 3'-UTR plays an important role in enhancing the translation efficiency of the gene that forms the coding region (CR) or its transcript, and in maintaining the mRNA transcript stably in the cell without degradation.
[0063] mRNA expression constructs can also include a transcription control sequence (TCS) adjacent to the 5'-UTR to facilitate the transcription of polynucleotides. For example, the transcription control sequence (TCS) can be located on the 5' side of the 5'-UTR. There are no particular restrictions on such transcription control sequences (TCS).
[0064] The term "vector" in this disclosure refers to a construct that can be delivered to a host cell and is preferably configured to express one or more target genes or sequences. Some examples of vectors include viral vectors, DNA or RNA expression vectors, plasmids, granules or phage vectors, DNA or RNA expression vectors linked to a cationic condensing agent (CCA), DNA or RNA expression vectors packaged in liposomes, and specific eukaryotic cells such as producer cells.
[0065] Furthermore, constitutive or inducible promoters may be used in this disclosure as needed, depending on the specific circumstances as determined by those skilled in the art. A large number of promoters recognized by a variety of possible host cells are well known. The selected promoter can be efficiently linked to a nucleic acid molecule having a coding region (CR) consisting of an open reading frame (ORF) of a gene or transcript encoding a target peptide by removing the promoter from the source nucleic acid molecule via restriction enzyme digestion and inserting the isolated promoter sequence into the selected vector.
[0066] For example, when the vector of this disclosure is an expression vector and the host is a prokaryotic cell, it typically contains a potent promoter capable of driving transcription (e.g., tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pLλ promoter, pRλ promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, trp promoter, and T7 promoter). When using *Escherichia coli* as the host cell, the promoter and operon sites of the *E. coli* tryptophan biosynthesis pathway (Yanofsky, C., J. Bacteriol., 158:1018-1024 (1984)) and the left-handed promoter of phage λ (pLλ promoter, Herskowitz, I. and Hagen, D., Ann. Rev. Genet., 14:399-445 (1980)) can be used as regulatory sites.
[0067] Furthermore, when the vector of this disclosure is an expression vector and the host is a eukaryotic cell, promoters derived from mammalian cell genomes (e.g., metallothionein promoters), promoters derived from mammalian viruses (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus promoter, and HSV tk promoter), or promoters derived from bacteriophages (e.g., T7 promoter, T3 promoter, SM6 promoter) can be used, and the vector typically has a polyadenylated sequence as a transcription termination sequence.
[0068] Furthermore, when the recombinant vector of this disclosure is a reproducible expression vector, the recombinant vector may contain a replication origin, which is a specific nucleic acid sequence from which replication begins.
[0069] Meanwhile, as an exemplary example, the recombinant plasmid vector can be a vector in which expression is regulated by an inducible promoter, and as an example, the inducible promoter can be any of the following: T7 promoter, tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pLλ promoter, pRλ promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, and trp promoter. Preferably, the T7 promoter can be used.
[0070] The mRNA expression construct of this disclosure does not induce excessive T cell activation, and therefore has an advantage in terms of safety, as the risk of side effects (such as pericarditis) that can be caused by excessive T cell-induced responses is low. Furthermore, since IgG1 antibodies, a representative indicator of type 2 immune responses, are produced together with IgG2a, a representative indicator of type 1 immune responses, there is an advantage of a balanced occurrence of both type 1 and type 2 immune responses.
[0071] Type 1 immune response is an immune response derived from Th1 CD4 T cells, which secrete pro-inflammatory cytokines (such as IL-2 and IFN-γ) to induce the direct elimination of infectious antigens and the production of IgG2 antibodies. Type 2 immune response, on the other hand, is an immune response derived from Th2 CD4 T cells, which secrete cytokines (such as IL-4, IL-10, and IL-13) to induce tissue repair and the production of strong IgG1a antibodies.
[0072] Type 1 immune responses induce a strong inflammatory response to kill virus-infected cells and respond to the initial viral infection situation, while type 2 immune responses restore damaged tissues caused by inflammation and induce a long-term immune response through antibody production.
[0073] Therefore, in viral immunity, when either response is more dominant, it can lead to side effects due to an excessive immune response or weakened antiviral capacity due to an insufficient immune response. Thus, a balanced occurrence of type 1 and type 2 immune responses is the ideal therapeutic effect in mRNA vaccine therapy. Therefore, the mRNA expression construct of this disclosure represents a novel vaccine model in which type 1 and type 2 immune responses can occur in equilibrium.
[0074] This disclosure provides pharmaceutical compositions comprising mRNA constructs, gene constructs, and / or vectors.
[0075] Another aspect of this disclosure provides pharmaceutical compositions comprising: the above-described mRNA construct, gene construct, and / or vector; and a pharmaceutically acceptable vector.
[0076] The pharmaceutical compositions according to this disclosure may comprise a pharmaceutically acceptable carrier and may be formulated, according to conventional methods, into oral dosage forms (e.g., powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc.), topical formulations, suppositories, or sterile injectable solutions. The most preferred formulation of the pharmaceutical composition is an injectable solution.
[0077] When the pharmaceutical compositions of this disclosure are formulated as oral solid dosage forms, they include tablets, pills, powders, granules, capsules, etc., and such solid dosage forms may contain at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc., and may contain, but are not limited to, lubricants (such as magnesium stearate or talc).
[0078] When the pharmaceutical compositions of this disclosure are formulated as oral liquid preparations, they include suspensions, solutions, emulsions, syrups, etc., and contain, but are not limited to, diluents (e.g., water or liquid paraffin), wetting agents, sweeteners, flavoring agents, and preservatives.
[0079] When the pharmaceutical compositions of this disclosure are formulated for parenteral use, they include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories, and the non-aqueous solvents and suspensions include, but are not limited to, propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable esters (e.g., ethyl oleate). As a base for suppositories, witepsol, polyethylene glycol (… Tween 61, cocoa butter, laurate ( ), glycerin gelatin, etc., but not limited to these.
[0080] Pharmaceutical compositions may be administered once or multiple times in a pharmaceutically effective amount. As used herein, the term "pharmaceutically effective amount" means an amount sufficient to prevent or treat disease without impairing the efficacy of a therapeutic agent (especially when administered in combination with a therapeutic agent) given a reasonable benefit / risk ratio applicable to medical immunomodulation, and the effective dose level can be determined based on factors including: the severity of the disease, the activity of the drug, the patient's age, weight, health status, and sex, the patient's sensitivity to the drug, the time and route of administration, the excretion rate of the compositions of this disclosure, the duration of treatment, drugs used in combination with or concurrently with the compositions used in this disclosure, and other factors known in the medical field.
[0081] The pharmaceutical compositions according to this disclosure can be administered to mammals, such as rats, mice, livestock and humans, via a variety of routes, including but not limited to oral administration, intrathecal, intraauricular, intraperitoneal or intravenous, intramuscular, subcutaneous, intrauterine, epidural, sublingual or intracerebral injection.
[0082] The pharmaceutical compositions disclosed herein may contain an mRNA construct, gene construct, or vector in an amount ranging from 0.01% to 95% by weight, preferably from 1% to 80% by weight, based on the total weight of the composition.
[0083] The mRNA constructs, gene constructs, and / or vectors disclosed herein are configured to enter and be expressed in mammalian cells. Such configurations can be particularly useful for the treatment and / or prevention of diseases. Numerous methods exist for expressing mRNA constructs, gene constructs, and / or vectors in host cells, and any suitable method may be used.
[0084] For example, mRNA constructs, gene constructs and / or vectors according to this disclosure can be inserted into viral vectors such as encephalomyocarditis virus (EMCV), adenovirus, adeno-associated virus, retrovirus, vaccinia virus or other poxviruses (e.g., fowlpox virus).
[0085] According to one exemplary implementation, the above-described mRNA construct can be inserted into a suitable vector and subsequently converted into a nucleic acid molecule in RNA form via in vitro transcription (IVT).
[0086] Many vectors available and known in the art can be used for the purposes of this disclosure. The selection of a suitable vector will depend primarily on the size of the nucleic acid molecule to be inserted into the vector and the specific host cell to be transformed by the vector.
[0087] The pharmaceutical composition also comprises lipid nanoparticles (LNPs), polymeric microparticles, and oil-in-water emulsions. For example, polynucleotides, RNA, cRNA, or self-replicating RNA are encapsulated in LNPs, polymeric microparticles, and oil-in-water emulsions, binding to or adsorbing onto the LNPs, polymeric microparticles, and oil-in-water emulsions. In one example, polynucleotides are encapsulated in LNPs, polymeric microparticles, and oil-in-water emulsions, binding to or adsorbing onto the LNPs, polymeric microparticles, and oil-in-water emulsions. In another example, RNA is encapsulated in LNPs, polymeric microparticles, and oil-in-water emulsions, binding to or adsorbing onto the LNPs, polymeric microparticles, and oil-in-water emulsions.
[0088] In one example, the pharmaceutical composition also comprises an LNP. For example, the mRNA construct is encapsulated in an LNP. In another example, RNA is encapsulated in an LNP. In yet another example, RNA is adsorbed onto an LNP.
[0089] In one instance, the LNP contains PEG-lipids, structured lipids, and / or neutral lipids. For example, the LNP contains PEG-lipids, structured lipids, and / or neutral lipids. In another instance, the LNP contains PEG-lipids, structured lipids, and / or neutral lipids. In one instance, the LNP also contains cationic lipids. In another instance, the LNP does not contain cationic lipids.
[0090] In one example, the pharmaceutical composition further comprises polymeric microparticles. For example, a polynucleotide is encapsulated in the polymeric microparticles. In another example, RNA is encapsulated in the polymeric microparticles. In yet another example, RNA binds to the polymeric microparticles. In yet another example, RNA is adsorbed onto the polymeric microparticles.
[0091] In one example, the pharmaceutical composition further comprises an oil-in-water emulsion. For example, a polynucleotide is encapsulated in an oil-in-water emulsion. In another example, RNA is encapsulated in an oil-in-water emulsion. For example, RNA is bound to an oil-in-water emulsion.
[0092] This disclosure provides a method for preventing or treating a disease or condition in a subject, the method comprising administering a pharmaceutical composition of this disclosure to a subject in need of such treatment.
[0093] This disclosure provides the use of the pharmaceutical compositions of this disclosure in the preparation of a medicament for the prevention or treatment of a disease or condition in a subject in need of such medicament.
[0094] This disclosure provides a method for inducing an immune response in a subject, comprising administering the pharmaceutical composition of this disclosure to a subject in need of doing so.
[0095] This disclosure also provides the use of the pharmaceutical compositions of this disclosure in the preparation of a medicament for inducing an immune response in a subject in which such a need exists.
[0096] The term "object" in this disclosure includes animals or humans whose symptoms can be relieved by administration of a pharmaceutical composition according to this disclosure.
[0097] The term "administration" in this disclosure means the introduction of a predetermined substance into a human or animal by any suitable method, and the route of administration of the pharmaceutical composition according to this disclosure may be oral or parenteral via any common route, as long as it can reach the target tissue. Additionally, the pharmaceutical composition according to this disclosure can be administered via any device that allows the active ingredient to migrate to target cells.
[0098] This disclosure also provides immunogenic compositions comprising mRNA constructs, gene constructs, vectors and / or pharmaceutical compositions for use as vaccines.
[0099] For example, administration of the composition induces humoral and / or cell-mediated immune responses. In one instance, the composition induces a humoral immune response in a subject. For example, the humoral immune response is an antibody-mediated immune response. In another instance, the composition induces a cell-mediated immune response. For example, a cell-mediated immune response induces antigen-specific cytotoxicity and helper T cell activation.
[0100] Such immunogenic compositions may also contain adjuvants.
[0101] The term "adjuvant" in this disclosure generally refers to any substance that enhances a humoral or cellular immune response against an antigen. Adjuvants serve two purposes: they slow the release of antigens from the injection site and they stimulate the immune system.
[0102] Adjuvants include protamine, nucleolar protein, spermine, spermidine, and cationic polysaccharides, as well as stable cationic peptides or polypeptides, particularly chitosan, TDM, MDP, muramyl dipeptide, pluronic, alum solution, aluminum hydroxide, ADJUMER (polyphosphazene); aluminum phosphate gel; algal dextran; algammulin; aluminum hydroxide gel (alum); highly protein-adsorbing aluminum hydroxide gel; low-viscosity aluminum hydroxide gel; AF or SPT (squalane (5%), Tween 80 (0.2%), PLURONIC-L121 (1.25%), phosphate-buffered saline, pH 7.4 emulsion); AVRIDINE (propylene diamine); BAY R1005 (N-(2-deoxy-2-L-leucine-amino-bD-pyranoglycosyl)-N-octadecyldodecanoyl-amidoacetate); CALCITRIOL (1α,25-dihydroxy-vitamin D3); calcium phosphate gel; CAP™ (calcium phosphate nanoparticles); cholera toxin, cholera toxin-A1-protein-AD-fragment fusion protein, cholera toxin subunit B; CRL 1005 (block copolymer P1205); liposomes containing cytokines; DDA (dimethyl dioctadecyl ammonium bromide); DHEA (dehydroepiandrosterone); DMPC (myristoyl phosphatidylcholine); DMPG (myristoyl phosphatidylglycerol); DOC / alum complex (sodium deoxycholate); Freund's complete adjuvant; Freund's incomplete adjuvant; γ-inulin; Gerbu adjuvant (a mixture of N-acetylglucosamine-(P1-4)-N-acetylmuracil-L-alanyl-D-glutamine (GMDP), dimethyl dioctadecyl ammonium chloride (DDA), and zinc-L-proline salt complex (ZnPro-8); GM- CSF); GMDP (N-acetylglucosamine-(b1-4)-N-acetylmuracil-L-alanyl-D-isoglutamine); imiquimod (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinoline-4-amine); ImmTher (N-acetylglucosamine-N-acetylmuracil-L-Ala-D-isoGlu-L-Ala-dipalmitate); DRV (immunoliposomes prepared from dehydrated-rehydrated vesicles); interferon-γ; interleukin-1β; interleukin-2; interleukin-7; interleukin-12; ISCMS (“immunostimulatory complexes”); ISCOPREP 7.0.3.Liposomes; LOXORIBINE (7-allyl-8-oxoguanosine (guanine)); LT oral adjuvant (E. coli unstable enterotoxin-protoxin); microspheres and particles of the composition; MF59 (squalene-water emulsion); MONTANIDE ISA 51 (purified incomplete Freund's adjuvant); MONTANIDE ISA 720 (metabolizable oil adjuvant); MPL (3-Q-deacylated-4'-monophosphoryl lipid A); MTP-PE and MTP-PE liposomes (N-acetyl-L-alanyl-D-isoglutamin-L-alanine-2-(1,2-dipalmitoyl-sn-glycerol-3-(hydroxyphosphoryloxy))-ethylamide, monosodium salt); MURAMETIDE (Nac-Mur-L-Ala-D-Gln-OCH3); MURAPALMITINE and D-MURAPALMITINE (Nac-Mur-L-Thr-D-isoGln-sn-dipalmitoylglycerol); NAGO (neuraminidase-galactose oxidase); nanospheres or nanoparticles of the composition; NISV (nonionic surfactant vesicles); PLEURAN (β-glucan); PLGA, PGA, and PLA (homomers and copolymers of lactic acid and glycolic acid; microspheres / nanospheres); PLURONIC L121; PMMA (polymethyl methacrylate); PODDS (protein-like microspheres); polyurethane derivatives; poly-rA:poly-rU (polyadenylate-polyuridine complex); polysorbate 80 (Tween 80); protein spirochetes (Avanti Polar Lipids, Inc.).Alabaster (AL); STIMULON (QS-21); Quil-A (Quil-A saponin); S-28463 (4-amino-otec-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]-quinoline-1-ethanol); SAF-1 (“Syntex adjuvant”); Sendai virus protein liposomes and lipid matrices containing Sendai virus; Span-85 (sorbitol trioleate); Spector (Marcol 52, Span Emulsions of Tween 85 and Tween 85); squalene or Robane (2,6,10,15,19,23-hexamethyltetracosane and 2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-docosahexaene); stearoyltyrosine (octadecyltyrosine hydrochloride); Theramid (N-acetylglucosamine-N-acetylmuracil-L-Ala-D-isoGlu-L-Ala-dipalmitoyloxypropylamide); threonyl-MDP (Termurtide or [thr-1]-MDP; N-acetylmuracil-L-threonyl-D-isoglutamine); Ty particles (Ty-VLP or virus-like particles); Walter-Reed liposomes (liposomes containing lipid A adsorbed on aluminum hydroxide); etc.
[0103] This disclosure provides pharmaceutical compositions for the prevention or treatment of viral infections, comprising mRNA constructs, gene constructs, and / or vectors.
[0104] For example, viral infections can be associated with influenza, rhinovirus, respiratory syncytial virus, coronavirus, Coxsackievirus, echovirus, Nipah virus, dengue virus, norovirus, rotavirus, SFTS virus, etc. Therefore, the target peptide encoded by the RNA sequence can be a viral antigen. More specifically, RNA sequences can encode peptides derived from: orthomyxoviruses (e.g., influenza A, B, and C), paramyxoviridae viruses (pneumoviruses (e.g., respiratory syncytial virus (RSV), bovine respiratory syncytial virus, mouse pneumonia virus, and turkey rhinotracheitis virus), paramyxoviruses (PIVs) such as Nipah virus, and metapneumoviruses such as human metapneumovirus (hMPV) and avian metapneumovirus (aMPV)), picornaviruses (e.g., rhinovirus, echovirus, Coxsackievirus)), and coronaviruses (e.g., severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), SARS coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), avian infectious bronchitis virus (IBV), and mouse hepatitis virus (MHV)).
[0105] Preferably, it can be an RNA sequence encoding a peptide derived from SARS coronavirus 2 (SARS-CoV-2). For example, it can be a sequence encoding the spike (S) protein and / or nucleocapsid (N) peptide of SARS coronavirus 2 (SARS-CoV-2) or a known mutant thereof. For example, it can be an Alpha, Beta, Gamma, Delta, Lambda, or Omicron variant. According to one embodiment of this disclosure, the RNA encoding a peptide derived from SARS coronavirus 2 (SARS-CoV-2) is RNA encoding an Omicron variant antigen. An exemplary sequence thereof is shown in SEQ ID NO: 4, and an antigen sequence prepared therefrom is shown in SEQ ID NO: 12.
[0106] [Beneficial Effects]
[0107] This disclosure presents a novel mRNA expression platform, a new uncapped / unmodified mRNA expression system that does not use a 5'-cap and m1Ψ-modified uridine nucleic acid, and effectively induces an immune response while exhibiting excellent antigen expression. Therefore, this platform is economical due to the avoidance of conventional and expensive 5'-cap / m1Ψ, and prevents protein translation errors caused by frameshift, a problem in conventional mRNA expression systems containing m1Ψ. Furthermore, it provides a more natural and cell-friendly mRNA expression system through the use of a translation system evolved from viruses.
[0108] Furthermore, the novel mRNA expression platform of this disclosure has low viral toxicity and low toxicity of the administered substance, thereby providing improved side effects compared to existing mRNA vaccines.
[0109] Furthermore, in the case of the EMCV-IRES vaccine, not only IgG1 antibodies (which are a representative indicator of type 2 immune response) are produced, but also IgG2a (which are an indicator of type 1 immune response). Therefore, the EMCV-IRES vaccine has a significant effect because both type 1 and type 2 immune responses can occur in a balanced manner. Attached Figure Description
[0110] Figure 1 This is a diagram illustrating a vector construct for the EMCV-IRES mRNA expression platform according to this disclosure.
[0111] Figure 2 This is a diagram illustrating a vector construct designed for expressing the Omicron spike protein in the EMCV-IRES mRNA expression platform according to this disclosure.
[0112] Figure 3The determination is shown based on Figure 2 The results of Omicron-spike protein expression prepared by the vector construct.
[0113] Figure 4 The results show the in vivo expression effects after the designed EMCV-IRES mRNA expression platform was encapsulated in LNP and subsequently administered to mice.
[0114] Figure 5 The results show the formation of target antigen-specific antibodies after administration of the EMCV-IRES mRNA expression platform, which is designed to express the Omicron-spike gene, to mice.
[0115] Figure 6 The results show the formation of neutralizing antibodies after administration of the EMCV-IRES mRNA expression platform, which was designed to express the Omicron-spike gene, to mice.
[0116] Figure 7 The results demonstrate the enhancement of target antigen-specific T cell responses after administration of the EMCV-IRES mRNA expression platform, designed to express the Omicron-spike gene, to mice.
[0117] Figure 8 The results show the changes in body weight after administering the EMCV-IRES mRNA expression platform, designed to express the Omicron-spike gene, to hACE2 transgenic mice.
[0118] Figure 9 The results of evaluating macroscopic pneumonia lesions based on the rate of improvement (%) after administration of the EMCV-IRES mRNA expression platform designed to express the Omicron-spike gene to hACE2 transgenic mice are shown.
[0119] Figure 10 Results show the results determining the level of immune-neutralizing antibody production after administration of the EMCV-IRES mRNA expression platform, designed to express the Omicron-spike gene, to hACE2 transgenic mice.
[0120] Figure 11 Results show the survival rates determined after administering the EMCV-IRES mRNA expression platform, designed to express the Omicron-spike gene, to hACE2 transgenic mice. Detailed Implementation
[0121] The present disclosure will be described in more detail below by way of embodiments. However, these embodiments are provided to illustrate the present disclosure, and the scope of the present disclosure is not limited to these embodiments.
[0122] Example 1. Design of the EMCV-IRES mRNA expression system
[0123] To construct an expression system configuration that can express mRNA well regardless of whether capping is performed, a vector was designed using the following sequences. For this purpose, the 3'-UTR and 5'-UTR derived from poliovirus were used with EMCV-IRES. Specifically, as... Figure 1 As shown, the vector was constructed such that EMCV-IRES was located after the 5'-UTR, and the target gene (GOI) was located after it for expression, followed by the 3'UTR and poly(A).
[0124] Table 1
[0125]
[0126] As an example, a vector was constructed by incorporating the spike protein of the SARS-CoV-2 Omicron virus into the EMCV-IRES mRNA expression platform. The structure of the spike protein was analyzed to predict the optimal spike protein sequence, shown in SEQ ID NO:4. This was used as the GOI described above. To clone into the EMCV-IRES mRNA vector, the GOI was cloned into a plasmid vector using restriction enzymes and DNA ligase, and the plasmid DNA was purified. IVT mRNA (in vitro transcribed mRNA) was then synthesized using unmodified uridine, and an exemplary structure of it is shown in [image missing]. Figure 2 The poly(A) contained in the vector is shown in SEQ ID NO: 5, and the full-length sequence of the vector is shown in SEQ ID NO: 6.
[0127] Example 2. Design of the IRES mRNA Expression System
[0128] As in Example 1 above, the following sequence was used to design a vector to construct an expression system that can effectively express mRNA regardless of whether it is capped.
[0129] The sequences for replacing the EMCV-IRES, 5'-UTR and 3'-UTR shown in SEQ ID NO: 1, 2 and 3 respectively are listed in Table 2 below.
[0130] Table 2
[0131]
[0132] An expression system was constructed by combining the IRES, 5'-UTR, and 3'-UTR described above in a similar manner to Example 1.
[0133] Example 3. Determining the expression of target antigens in cells using the EMCV-IRES mRNA expression system.
[0134] The EMCV-IRES mRNA expression system containing the SARS-CoV-2 Omicron spike gene, prepared in Example 1, was encapsulated in LNPs and subsequently transfected into the Huh-7 cell line. The expression efficiency of the spike antigen was then analyzed by Western blotting after 48 hours.
[0135] In particular, to compare with existing 5' capped / m1Ψ mRNA expression systems, mRNA containing a 5' cap, m1Ψ, and β-globin 5'UTR and expressing the Omicron spike antigen was used as a control and encapsulated in LNPs to compare expression efficiency.
[0136] The results are shown in Figure 3 middle.
[0137] As from Figure 3 As can be seen, the expression of the target antigen (Omicron spike protein) using the EMCV-IRES mRNA expression platform was determined to be higher than that of the control 5' capped / m1Ψ mRNA expression system. This establishes that the expression system according to this disclosure can stably express the target antigen in vivo in high yield without capping, compared to existing systems.
[0138] Example 4. In vivo expression of target antigens using the EMCV-IRES mRNA expression system
[0139] To investigate in vivo protein expression via the EMCV-IRES mRNA expression system, the EMCV-IRES mRNA expression system containing the luciferase gene was encapsulated in LNPs and injected intramuscularly into BALB / c mice. The level of luciferase expression in the muscle was determined after 24 hours.
[0140] The EMCV-IRES mRNA expression system containing the luciferase gene was prepared as follows: Specifically, in the LNP-encapsulated EMCV-IRES mRNA expression system (mRNA vaccine), the amount of encapsulated mRNA in the mRNA vaccine was precisely measured using a RiboGreen assay. The mRNA vaccine was then diluted with PBS to obtain encapsulated mRNA amounts of 1 μg / 50 μl and 2.5 μg / 50 μl. The appropriate concentrations of the EMCV-IRES mRNA expression system were injected into the quadriceps femoris region of Balb / c mice using an insulin injector. After 24 hours, D-luciferin (3 mg in 200 μl) was injected intraperitoneally into the mice, and the emitted fluorescence was measured for 60 seconds using a BLI system after 10 minutes to determine the luciferase expression level resulting from the administration of the mRNA vaccine to the muscle site.
[0141] As a control, standard mRNA expression systems (β-globin / modified or β-globin / unmodified mRNA expression systems) containing β-globin 5'-UTR with a 5'-cap and prepared using m1Ψ-modified uridine or normal uridine were encapsulated with the same LNP and used.
[0142] The above experimental results are shown in Figure 4 middle.
[0143] like Figure 4 As shown, it was determined that the expression level of luciferase protein increased with increasing expression system dose in all groups injected with mRNA-LNP (mRNA vaccine). Similar to previous reports, the β-globin / modified expression system exhibited higher in vivo protein expression efficiency; however, the EMCV-IRES expression system according to this disclosure was also determined to induce protein expression similarly to the β-globin / unmodified expression system, demonstrating its high potential for use as an mRNA expression system.
[0144] Example 5. Generation of target antigen-specific antibodies by administering the EMCV-IRES mRNA expression system
[0145] The EMCV-IRES mRNA expression system or β-globin / modified mRNA expression system containing the Omicron spike gene, prepared in Example 1, was administered intramuscularly to BALB / c mice twice at 3-week intervals. For LNP-encapsulated mRNA vaccines (EMCV-IRES, β-globin, modified), the amount of encapsulated mRNA in the mRNA vaccine was accurately measured using the RiboGreen assay. The mRNA vaccine was diluted with PBS to an encapsulated mRNA amount of 5 μg / 50 μl. This concentration of mRNA vaccine was injected twice into the quadriceps femoris region of Balb / c mice using an insulin syringe at 3-week intervals, and approximately 250 μl of blood was obtained from the mice two weeks after the last administration date using a retroorbital blood collection. The blood was centrifuged at 13,300 rpm for 20 minutes at 4°C, and approximately 150 μl of supernatant serum was obtained. The titer of Omicron spike protein-specific IgG antibodies in the serum was then analyzed by ELISA, and the results are shown in [Figure / Table / Insert Table ... Figure 5 middle.
[0146] The negative control group was the group given PBS, and the positive control group was given the spike hexapro protein and the vaccine adjuvant (Addavax).
[0147] like Figure 5 As can be seen, the level of Omicron spike protein-specific IgG antibodies produced in the group administered the EMCV-IRES expression system was higher than that in the group administered the β-globin / modified expression system. Furthermore, the EMCV-IRES expression system group also exhibited higher IgG1 and IgG2a titers when IgG subtype responses were determined, establishing its high potential as an mRNA expression system.
[0148] The above results indicate that although conventional protein expression systems only generate IgG1 antibodies (which are type 2 responses), the mRNA expression system according to this disclosure can also generate IgG2a antibodies (a type 1 response that is effective against viral infection).
[0149] In this respect, type 1 immune responses induce strong inflammatory responses to kill virus-infected cells and respond to the initial viral infection situation, while type 2 immune responses repair wound tissue caused by inflammation and induce long-term immune responses through antibody production.
[0150] In viral immunity, when one response is more dominant, it can lead to side effects due to an overactive immune response or weakened viral resistance due to an insufficient immune response. Therefore, the ideal outcome is for type 1 and type 2 immune responses to occur in a 1:1 ratio. In the case of the mRNA expression system according to this disclosure, since it produces not only IgG1 antibodies (a representative indicator of type 2 immune response) but also IgG2a (an indicator of type 1 immune response), thus achieving a balanced response between type 1 and type 2 immune responses, this vaccine system exhibits superior efficacy.
[0151] Example 6. Generation of neutralizing antibodies by administration of the EMCV-IRES mRNA expression system
[0152] BALB / c mice were intramuscularly injected twice at 3-week intervals with 5 μg of the EMCV-IRES mRNA expression system containing the Omicron spike gene prepared in Example 1 or the β-globin / modified mRNA expression system. The level of Omicron spike-specific neutralizing antibody production in serum was then determined.
[0153] The efficacy of neutralizing antibodies was determined by measuring the extent to which antibodies produced by the expression system inhibited pseudovirus infection of Huh-7 cells expressing the Omicron spike protein; in particular, PRNT50 was measured by serum dilution at which serum from mice injected with the expression system inhibited pseudovirus infection by 50%.
[0154] The results are shown in Figure 6 From the middle. For example, from Figure 6 It can be seen that the serum of mice injected with the EMCV-IRES mRNA expression system had better pseudovirus infection inhibition (lower PRNT50 value) compared with the β-globin / modified expression system.
[0155] Example 7. Generating target antigen-specific T cell responses by administering the EMCV-IRES mRNA expression system
[0156] The EMCV-IRES expression system containing the Omicron spike gene, prepared in Example 1, was administered intramuscularly to BALB / c mice twice at 3-week intervals, at a dose of 5 μg. Splenic T cells were then stimulated with the Omicron spike peptide complex, and antigen-specific T cell responses were investigated using intracellular cytokine staining (ICS) to measure the ratio of IFN-γ+ / TNF-α+ T cells producing cytokines IFN-γ and TNF-α. Specifically, the amount of mRNA encapsulated in the LNP-encapsulated mRNA vaccine (EMCV-IRES, β-globin, modified) was first precisely measured using a RiboGreen assay. The mRNA vaccine was then diluted with PBS to a dose of 5 μg / 50 μl. This concentration of mRNA vaccine was injected twice at 3-week intervals into the quadriceps region of Balb / c mice using an insulin syringe, and the mice were dissected to remove the spleen 2 weeks after the last administration. Spleens were milled using a 70 μm filter to release cells at the single-cell level. Red blood cells were removed using RBC lysis buffer to obtain only immune cells from the spleen. Equal volumes of cells were plated, treated with Omicron spike peptide conjugate, and subsequently cultured at 37°C and 5% CO2 for 5 hours. Subsequently, cells were stained with antibodies against IFN-γ and TNF-α for 20 minutes to identify IFN-γ+ / TNF-α+ T cells exhibiting Omicron antigen-specific reactivity. The proportion of stained T cells in total T cells was measured by flow cytometry to determine the proportion of T cells exhibiting Omicron-specific reactivity, and the results are shown in [Table data would be inserted here]. Figure 7 middle.
[0157] As from Figure 7 As can be seen, a significantly enhanced IFN-γ+ / TNF-α+ T cell response was identified in the mRNA expression system group compared to the PBS administration group, which served as a negative control. This establishes the high potential of the EMCV-IRES mRNA expression system of this disclosure for use as a vaccine.
[0158] Example 8. Evaluation of the potency of the expression system candidate material (EMCV-IRES) using a SARS-CoV-2 hACE2 transgenic mouse infection model.
[0159] To evaluate the efficacy of the EMCV-IRES expression system containing the Omicron-spike gene prepared in Example 1, the expression system was inoculated twice at 3-week intervals, and administered via intranasal instillation of 50 μl (1.0 × 10⁻⁶) at week 7 from the start date of the experiment. 4hACE2 transgenic mice were infected with SARS-CoV-2 virus (Wuhan strain) at PFU / mL. Then, the mice were necropsy on day 7 post-infection (PID7) to evaluate macroscopic pneumonia lesions and measure neutralizing antibody titers against SARS-CoV-2.
[0160] Experimental animals were randomly selected from 34 female hACE2 transgenic mice (B6.Cg-Tg(K18-ACE2)2Prlmn / J, JAX #034860) (6 weeks old) and assigned to the planned number of experimental animals for each group.
[0161] The allocation of experimental animal groups is described in Table 3 below.
[0162] Table 3
[0163]
[0164] The initial vaccination of the positive control group (PC) and the expression system administration group (EMCV-IRES) was performed on the start date of the experiment, and a second vaccination was performed 3 weeks after the initial vaccination date, for a total of 2 vaccinations at 3-week intervals, by intramuscular injection of 50 μl into the hind thigh muscle of the experimental animals. Mortality and general clinical signs were monitored twice a week from the date of the first vaccination with the test substance until excluding the day of infection (day 0 post-infection; PID0); and daily from the day of infection (day 0 post-infection; PID0) until day 7 post-infection (PID7). The weight of the experimental animals was measured weekly from the date of the first vaccination with the test substance until excluding the day of infection (day 0 post-infection; PID0); and on days 0, 2, 4, and 7 post-infection during the period from the day of infection (day 0 post-infection; PID0) to day 7 post-infection (PID7). All animals underwent necropsy to evaluate macroscopic pneumonia lesions in the lungs, and serum was collected during necropsy to measure SARS-CoV-2 neutralizing antibody titers. Changes in body weight of the test animals are described in [details omitted]. Figure 8In particular, all experimental groups showed a gradual increase in body weight from the start of the test (week 0) to the date of viral inoculation (week 7). Based on body weight on day 0 post-infection (PID 0), the viral infection group (VC) showed a weight change rate of approximately -9.9% on day 7 post-infection (PID 7; post-mortem day). The weight change rate in the positive control group (PC) was -11.2%, and in the expression system administration group (EMCV-IRES) it was -4.8%. In particular, such administration of the EMCV-IRES system showed low weight loss, indicating fewer side effects compared to existing known mRNA vaccine systems. Weight loss is one of the representative indicators for measuring viral toxicity and the toxicity of the administered substance. The fact that the positive control group showed a higher level of weight loss after infection than the viral infection group suggests that, in addition to the weight loss caused by viral infection, the positive control group itself was highly toxic, leading to additional weight loss in the mice. Conversely, in the case of the expression system administration group (EMCV-IRES) according to this disclosure, the measured rate of weight loss was lower than that in the viral infection group. These results confirm that the EMCV-IRES mRNA expression system according to this disclosure has a significant effect in improving side effects because it relatively inhibits the virus while the drug itself has low toxicity to mice.
[0165] Animals underwent necropsy on day 7 post-infection (PID7) to determine the rate of improvement in macroscopic pneumonia lesions and macroscopic findings. Results are shown in... Figure 9 From the middle. For example, from Figure 9 As can be seen, macroscopic changes caused by viral infection, including congestion / hemoptysis and edema, were observed in the lungs of all experimental groups. When the improvement rate of pneumonia lesions in each experimental group was calculated based on the viral infection group (VC), the positive control group (PC) showed an average improvement rate of 50.9%, and the expression system administration group (EMCV-IRES) showed an average improvement rate of 53.6%, confirming its superior efficacy compared to conventional known mRNA expression systems.
[0166] Determine the level of neutralizing antibody production and show it. Figure 10 From the middle. For example, from Figure 10 As can be seen, no neutralizing antibody titers were detected in the virus infection group (VC), the mean IgG neutralizing antibody titer against the SARS-CoV-2 spike RBD protein was measured in the positive control group (PC) at 209,586 ng / ml, and the mean IgG neutralizing antibody titer in the expression system administration group (EMCV-IRES) was measured at 246,533 ng / ml, confirming that it showed superior performance compared to conventional known mRNA expression systems.
[0167] Additionally, regarding the survival rate of test animals from the day of infection (day 0 post-infection; PID0) to day 7 post-infection (PID7), the analysis results are shown in... Figure 11 In the case of the expression system administration group (EMCV-IRES) according to this disclosure, the survival rate was 100%. In contrast, the virus infection group (VC) showed a survival rate of only 70% on day 7, and the positive control group (PC) showed a survival rate of 75%, establishing that animals administered the mRNA expression system exhibited a high survival rate.
Claims
1. The mRNA construct, from 5' to 3', contains: a 5'-UTR region; an internal ribosome entry site (IRES) regulatory element; an RNA sequence encoding the target peptide; a 3'-UTR region; and a poly(A) nucleotide sequence.
2. The mRNA construct of claim 1, wherein the mRNA construct does not contain a 5' cap structure.
3. The mRNA construct of claim 1, wherein the mRNA construct does not contain modified nucleic acids.
4. The mRNA construct of claim 1, wherein the 5'-UTR region is a cloverleaf structure of poliovirus, rhinovirus, or Coxsackievirus.
5. The mRNA construct of claim 1, wherein the 5'-UTR region comprises any one of the nucleic acid sequences selected from SEQ ID NO: 2, 8 and 9, a nucleic acid sequence having at least 80% homology therewith, a fragment thereof or a functional variant thereof.
6. The mRNA construct of claim 1, wherein the 5'-UTR region comprises the cloverleaf structure of poliovirus SEQ ID NO: 2, a nucleic acid sequence having at least 80% homology therewith, a fragment thereof, or a functional variant thereof.
7. The mRNA construct of claim 1, wherein the 3'-UTR region is the 3'-UTR of poliovirus, rhinovirus, or Coxsackievirus.
8. The mRNA construct of claim 1, wherein the 3'-UTR region comprises any one of the nucleic acid sequences selected from SEQ ID NO: 3, 10 and 11, a sequence having at least 80% homology therewith, a fragment thereof or a functional variant thereof.
9. The mRNA construct of claim 1, wherein the 3'-UTR region comprises the 3'-UTR of the poliovirus of SEQ ID NO: 3, a nucleic acid sequence having at least 80% homology therewith, a fragment thereof, or a functional variant thereof.
10. The mRNA construct of claim 1, wherein the internal ribosome entry site (IRES) regulatory element is an IRES derived from encephalomyocarditis virus or an IRES derived from Coxsackie virus.
11. The mRNA construct of claim 10, wherein the IRES regulatory element comprises any nucleic acid sequence selected from SEQ ID NO: 1 or 7, a sequence having at least 80% homology thereto, a fragment thereof, or a functional variant thereof.
12. The mRNA construct of claim 1, wherein the 5'-UTR region comprises the nucleic acid sequence of SEQ ID NO: 2, a sequence having at least 80% homology therewith, a fragment thereof, or a functional variant thereof; the internal ribosome entry site (IRES) regulatory element comprises the nucleic acid sequence of SEQ ID NO: 1, a sequence having at least 80% homology therewith, a fragment thereof, or a functional variant thereof; and the 3'-UTR region comprises the nucleic acid sequence of SEQ ID NO: 3, a sequence having at least 80% homology therewith, a fragment thereof, or a functional variant thereof.
13. The mRNA construct of claim 1, wherein the target peptide is a hormone, hormone analog, enzyme, enzyme inhibitor, receptor and receptor fragment, antigen and antigen fragment or analog, antibody and antibody fragment, single-chain antibody, structural protein or toxin protein.
14. The mRNA construct of claim 1, wherein the poly(A) nucleotide sequence is 20 nt to 500 nt in length.
15. A gene construct comprising a DNA nucleotide sequence corresponding to or complementary to the nucleotide sequence of the mRNA construct according to any one of claims 1 to 14.
16. A vector comprising the gene construct according to claim 15.
17. A method for producing mRNA with improved stability, comprising in vitro transcription using the vector of claim 16 as a template.
18. A pharmaceutical composition for the prevention or treatment of viral infections, comprising an mRNA construct according to any one of claims 1 to 14.
19. The pharmaceutical composition of claim 18 for the prevention or treatment of viral infection, wherein the viral infection is caused by a virus selected from the group consisting of: influenza virus, rhinovirus, respiratory syncytial virus, coronavirus, Coxsackie virus, echovirus, Nipah virus, dengue virus, norovirus, rotavirus, and SFTS virus.
20. The pharmaceutical composition of claim 18 for the prevention or treatment of viral infection, wherein the RNA sequence encoding the target peptide in the mRNA construct comprises an RNA sequence encoding a peptide derived from SARS coronavirus 2 (SARS-CoV-2).
